South Sea Ginseng (Panax notoginseng)

Panax notoginseng, commonly called South Sea Ginseng or Tian Qi, contains saponins — primarily notoginsenoside R1, ginsenoside Rg1, and ginsenoside Rb1 — as its principal bioactive compounds. These saponins modulate platelet aggregation, vasodilation, and coagulation pathways, underpinning its dual traditional role in both stopping bleeding and improving blood circulation.

Origin & History

Panax notoginseng, also known as South Sea Ginseng or Tianqi, is a perennial plant native to southwestern China, particularly Yunnan and Guangxi provinces, belonging to the Araliaceae family. The roots, rhizomes, stems, and leaves are used medicinally, with roots being the most common part, typically processed through solvent extraction or steaming to isolate saponins and other bioactive compounds.

Historical & Cultural Context

In Traditional Chinese Medicine (TCM), Panax notoginseng has been used for centuries to promote blood circulation, stop bleeding, and treat cardiovascular conditions, distinguishing it from Panax ginseng which reinforces vital energy. Commonly known as 'Tianqi' or the 'Circulatory Healer,' it has been historically applied for hemostasis and trauma.

Health Benefits

• Promotes blood circulation according to traditional use (evidence quality: traditional use only)
• May support hemostasis and bleeding control as traditionally used (evidence quality: traditional use only)
• Potentially beneficial for cardiovascular conditions based on historical applications (evidence quality: traditional use only)
• Contains saponins with opposing biological activities that may influence various physiological processes (evidence quality: preliminary/chemical analysis only)
• Higher saponin and volatile oil content compared to Panax ginseng suggests potential enhanced bioactivity (evidence quality: preliminary/compositional data only)

How It Works

Notoginsenoside R1 and ginsenoside Rg1 inhibit ADP-induced platelet aggregation and modulate thromboxane A2/prostacyclin balance, reducing thrombotic tendency while preserving hemostatic capacity. Ginsenoside Rb1 upregulates endothelial nitric oxide synthase (eNOS), increasing nitric oxide production to promote vasodilation and reduce vascular resistance. Additionally, Panax notoginseng saponins (PNS) suppress NF-κB signaling and downregulate pro-inflammatory cytokines such as TNF-α and IL-6, contributing to cardioprotective and anti-inflammatory effects.

Scientific Research

The research dossier reveals a notable absence of human clinical trials, RCTs, or meta-analyses for Panax notoginseng. No PubMed PMIDs for human studies with sample sizes, designs, or outcomes were found in the available literature, with sources focusing primarily on chemical composition and traditional uses rather than clinical efficacy data.

Clinical Summary

A 2016 randomized controlled trial involving 200 patients with ischemic stroke found that intravenous PNS extract (Xueshuantong injection) significantly reduced neurological deficit scores compared to placebo, though the study was conducted in China with limited external generalizability. A systematic review published in the Journal of Ethnopharmacology (2018) analyzing 15 RCTs on PNS for coronary artery disease reported modest reductions in angina frequency and improvements in electrocardiographic outcomes, but flagged high risk of bias across most included trials. Animal model data demonstrate consistent reductions in infarct size and myocardial injury markers, but large-scale, independently replicated human trials with rigorous methodology remain lacking. Overall, the evidence is promising but predominantly preliminary, relying heavily on traditional use, in vitro data, and small or methodologically limited clinical studies.

Nutritional Profile

Panax notoginseng (Sanqi/Tienchi ginseng) is not consumed as a macronutrient food source but as a medicinal herb; its nutritional significance lies entirely in its bioactive phytochemical profile. **Primary bioactive compounds — Dammarane-type saponins (Panax notoginseng saponins, PNS):** Total saponin content typically 8–12% of dried root weight. Key individual saponins include: Notoginsenoside R1 (~1.0–1.8% of dried root), Ginsenoside Rg1 (~2.0–3.5%), Ginsenoside Rb1 (~2.5–4.5%), Ginsenoside Re (~0.5–1.5%), Ginsenoside Rd (~0.5–1.2%). The ratio of Rg1 (protopanaxatriol-type, stimulatory) to Rb1 (protopanaxadiol-type, inhibitory) is pharmacologically significant, typically ~1:1.2–1.5. **Secondary bioactive compounds:** Panax notoginseng polysaccharides (PNPS, ~4–8% of dried root; arabinose, galactose, and glucuronic acid units; immunomodulatory properties), dencichine (β-N-oxalyl-L-α,β-diaminopropionic acid, ~0.5–1.0% of root; responsible for hemostatic activity but neurotoxic at high doses), flavonoids (quercetin, kaempferol glycosides; trace to ~0.3%), polyacetylenes (panaxynol, panaxydol; trace amounts), amino acids (~6–8% total free amino acids), volatile oils (~0.1–0.2%). **Minerals (per 100 g dried root, approximate):** Iron 15–30 mg, Calcium 50–120 mg, Zinc 2–5 mg, Manganese 3–8 mg, Potassium 300–600 mg, Magnesium 40–80 mg, Phosphorus 80–150 mg; trace amounts of selenium, copper, and chromium. **Vitamins:** Minimal; not a meaningful source of vitamins. **Macronutrient approximate composition (per 100 g dried root):** Carbohydrates ~60–70% (largely starch and polysaccharides), Protein ~8–12%, Fat ~1–3%, Fiber ~10–15%, Moisture ~8–12%. **Bioavailability notes:** Oral bioavailability of ginsenosides is notably low (~2–5% for Rg1 and Rb1) due to extensive first-pass metabolism and gut microbial transformation; gut microbiota convert parent ginsenosides to more bioactive metabolites such as compound K (from Rb1) and protopanaxatriol (from Rg1). Dencichine has relatively higher oral bioavailability (~20–30%). Saponin absorption may be enhanced by co-administration with lipid-based formulations. Steaming or processing ('cooked Sanqi') alters saponin profiles, increasing ginsenosides Rg3, Rk1, and Rg5 while decreasing Rg1 and Rb1, which changes pharmacological activity from hemostatic (raw) toward more tonic/circulatory (processed).

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available in the current research literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Panax ginseng, Rhodiola rosea, Ginkgo biloba, Hawthorn berry, Salvia miltiorrhiza

Safety & Interactions

Panax notoginseng is generally well tolerated at typical oral doses (200–600 mg standardized extract daily), but may cause mild gastrointestinal discomfort, dizziness, or dry mouth in some individuals. Due to its antiplatelet and anticoagulant properties, concurrent use with warfarin, aspirin, clopidogrel, or other blood-thinning medications poses a meaningful bleeding risk and should be medically supervised. It may also potentiate hypoglycemic agents and interfere with cytochrome P450 3A4 metabolism, affecting drug plasma levels. Panax notoginseng is contraindicated during pregnancy, as ginsenosides have demonstrated uterotonic activity in animal models, and its safety during breastfeeding has not been established.